uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

Core Viewpoint - DJS Law Group is investigating claims against uniQure N.V. for potential violations of securities laws following a significant drop in share price due to concerns raised by the FDA regarding the company's gene therapy for Huntington's disease [1][2]. Investigation Details - The investigation centers on whether uniQure made misleading statements or failed to disclose critical information to investors [2]. - On November 3, 2025, uniQure announced that the FDA may not consider the data from its Phase I/II studies of AMT-130 sufficient for a Biologics License Application (BLA) submission, leading to a more than 60% decline in share price [2]. Company Background - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, representing large hedge funds and alternative asset managers [4].